Therapeutic potential of neurotrophic factors in neurodegenerative diseases

The flavonoid fisetin promotes nerve cell survival from trophic factor withdrawal by enhancement of proteasome activity

To explore the possibility that specific flavonoids can substitute for neurotrophic factors, we examined the ability of the flavonol fisetin and several related flavonoids to support the survival of low density, serum-free cultures of rat cortical neurons. Normally these cells die within 24h in the absence of trophic factors but in the presence of fisetin and several related flavonoids the cells survive and produce long neurites. While the survival-promoting effect of several of the fisetin-related flavonoids was partially dependent on ERK activation, the effect of fisetin was not. Fisetin can enhance glutathione synthesis but the survival-promoting effect of fisetin was also not dependent on glutathione. However, proteasome inhibitors almost completely blocked the ability of fisetin to promote survival. Consistent with this observation, fisetin increased proteasome activity. Together these results demonstrate a new activity for fisetin and tie this activity to its neurotrophic effects.

Cellular analysis of S100Beta and fibroblast growth factor-2 in the dorsal root ganglia and sciatic nerve of rodents. focus on paracrine actions of activated satellite cells after axotomy

The role of satellite cells, a type of peripheral glia, in the paracrine mechanisms related to neuronal maintenance and plasticity in the dorsal root ganglia (DRG) needs to be further investigated. This study employed immunohistochemistry and image analysis to investigate basic fibroblast growth factor (bFGF, FGF-2) and S100Beta immunoreactivities in the DRG and sciatic nerve of the rat and mouse. Well-characterized antibodies against bovine (residues 1-24) and rat (residues 1-23) FGF-2 were employed. Furthermore, the state of satellite cell reaction and changes in the FGF-2/S100Beta immunoreactivity were analyzed after axotomy of rat sciatic nerve. Scattered neurons and the majority of the satellite cells of the rat DRG and also Schwann cells of the rat sciatic nerve stained for S100Beta. In the mouse, strong S100Beta was encountered in the majority of sensory neurons and Schwann cells. Moderate FGF-2 (residues 1-24) immunoreactivity was found in scattered small size neurons of the rat DRG. A strong FGF-2 (residues 1-23) immunoreactivity was achieved in the satellite cells of rat DRG. Both FGF-2 antisera showed strong labeling in the mouse DRG sensory neurons. Activated satellite cells of the axotomized DRG possessed increased amount of FGF-2 and S100Beta immunoreactivity as demonstrated by quantitative image analysis. The proximal stump of the lesioned rat sciatic nerve showed increased FGF-2 (residues 1-24 and 1-23) in the Schwann cells, myelin sheaths, and neuronal fibers, without changes in the level of S100Beta immunoreactivity. Results suggested a possible interaction between FGF-2 and S100Beta in activated satellite cells of the DRG, which might trigger paracrine actions in the axotomized sensory neurons.

Advancing translational research with the Semantic Web

BACKGROUND

A fundamental goal of the U.S. National Institute of Health (NIH) "Roadmap" is to strengthen Translational Research, defined as the movement of discoveries in basic research to application at the clinical level. A significant barrier to translational research is the lack of uniformly structured data across related biomedical domains. The Semantic Web is an extension of the current Web that enables navigation and meaningful use of digital resources by automatic processes. It is based on common formats that support aggregation and integration of data drawn from diverse sources. A variety of technologies have been built on this foundation that, together, support identifying, representing, and reasoning across a wide range of biomedical data. The Semantic Web Health Care and Life Sciences Interest Group (HCLSIG), set up within the framework of the World Wide Web Consortium, was launched to explore the application of these technologies in a variety of areas. Subgroups focus on making biomedical data available in RDF, working with biomedical ontologies, prototyping clinical decision support systems, working on drug safety and efficacy communication, and supporting disease researchers navigating and annotating the large amount of potentially relevant literature.

RESULTS

We present a scenario that shows the value of the information environment the Semantic Web can support for aiding neuroscience researchers. We then report on several projects by members of the HCLSIG, in the process illustrating the range of Semantic Web technologies that have applications in areas of biomedicine.

CONCLUSION

Semantic Web technologies present both promise and challenges. Current tools and standards are already adequate to implement components of the bench-to-bedside vision. On the other hand, these technologies are young. Gaps in standards and implementations still exist and adoption is limited by typical problems with early technology, such as the need for a critical mass of practitioners and installed base, and growing pains as the technology is scaled up. Still, the potential of interoperable knowledge sources for biomedicine, at the scale of the World Wide Web, merits continued work.

Verification of functional AAV-mediated neurotrophic and anti-apoptotic factor expression

The use of viral vectors for gene delivery offer many advantages for both basic research and therapeutic application through the continuous expression of a gene product within a target region. It is vital however that any gene product is correctly expressed in a biologically active form, and this should be confirmed prior to large scale in vivo studies. Using adeno-associated viral (AAV) vectors to direct the expression of either a neurotrophic factor or an anti-apoptotic protein, we have developed a range of in vitro assays to verify functional transgenic protein expression. Brain-derived neurotropic factor (BDNF) activity was confirmed by demonstrating enhanced generation of GABAergic neurons in embryonic (E15) striatal cultures and AAV-mediated glial-derived neurotrophic factor (GDNF) function using an assay for dopaminergic differentiation of embryonic (E14) ventral mesencephalic cultures. To assess functional anti-apoptotic factor expression we designed cell-survival assays, using embryonic cortical cultures to confirm Bcl-x(L) activity and the HT1080 cell-line for X-linked inhibitor of apoptosis protein (XIAP) activity following AAV-mediated expression. This study demonstrates that the use of functional assays provides valuable confirmation of desired biotherapeutic expression prior to extensive investigation with new gene delivery vectors.

A comparison of the neurotrophic activities of the flavonoid fisetin and some of its derivatives

Neurotrophic factors promote the development, maintenance and regeneration of nerve cells. Classical neurotrophic factors are proteins and thus not well-suited for therapeutic purposes. Recently, we showed that specific flavonoids such as fisetin (3, 7, 3', 4' tetrahydroxyflavone) promote the differentiation of nerve cells in culture through the activation of extracellular signal-regulated kinase (ERK) suggesting that flavonoids could substitute for neurotrophic factors. It has also been shown that fisetin promotes nerve cell survival following exposure to toxic oxidative insults. To determine whether or not this is unique to fisetin, a series of related compounds were assayed for neurotrophic activities. Many of these related compounds also promote nerve cell differentiation and are neuroprotective against toxic oxidative insults. However, the mechanisms underlying these neurotrophic effects differ among the compounds.

Midlife plasma insulin-like growth factor I and cognitive function in older men

CONTEXT

Emerging biological and epidemiological evidence suggests possible benefits of higher IGF-I levels in cognitive aging.

OBJECTIVE

The objective of the study was to examine the relation of midlife plasma IGF-I levels to late-life cognition.

DESIGN, SETTING, AND PARTICIPANTS

We conducted a secondary analysis from the Physicians' Health Study II, a prospective cohort of U.S. male physicians. Participants provided blood samples from 1982 to 1984 (mean age 57 yr). Using stored samples, we measured free IGF-I in 376 men and total IGF-I and IGF binding protein-3 in 460 men. Starting in 2001, we administered telephone-based tests of general cognition [the Telephone Interview of Cognitive Status (TICS)], verbal memory, and category fluency. We estimated multivariable-adjusted mean differences in cognitive performance across levels of free IGF-I and IGF-I to IGF binding protein-3 molar ratio.

MAIN OUTCOME MEASURES

Global score (averaging performance across all individual cognitive tests), the TICS, and a verbal memory score were measured.

RESULTS

Each sd increment in free IGF-I was associated with a multivariable-adjusted increase of 0.08 U (P = 0.02) on the global score. This mean difference was equivalent to that observed between men 2 yr apart in age: i.e. each sd increase in free IGF-I appeared cognitively equivalent to staying 2 yr younger. No significant mean differences in TICS scores were observed across free IGF-I levels. For verbal memory, each sd increment in free IGF-I was associated with an adjusted mean difference of 0.08 U (P = 0.03). Results appeared consistent for the molar ratio but were not statistically significant.

CONCLUSION

Higher midlife free IGF-I may be associated with better late-life cognition.

Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory

Small molecules that activate signaling pathways used by neurotrophic factors could be useful for treating CNS disorders. Here we show that the flavonoid fisetin activates ERK and induces cAMP response element-binding protein (CREB) phosphorylation in rat hippocampal slices, facilitates long-term potentiation in rat hippocampal slices, and enhances object recognition in mice. Together, these data demonstrate that the natural product fisetin can facilitate long-term memory, and therefore it may be useful for treating patients with memory disorders.

Ageing and neuronal vulnerability

Everyone ages, but only some will develop a neurodegenerative disorder in the process. Disease might occur when cells fail to respond adaptively to age-related increases in oxidative, metabolic and ionic stress, thereby resulting in the accumulation of damaged proteins, DNA and membranes. Determinants of neuronal vulnerability might include cell size and location, metabolism of disease-specific proteins and a repertoire of signal transduction pathways and stress resistance mechanisms. Emerging evidence on protein interaction networks that monitor and respond to the normal ageing process suggests that successful neural ageing is possible for most people, but also cautions that cures for neurodegenerative disorders are unlikely in the near future.

O método Lee Silverman para reabilitação da fala na doença de Parkinson

As alterações da fala (disfonia e disartria) frequentemente acompanham a evolução da doença de Parkinson (DP). Objetivo. Este estudo revisa o Método Lee Silverman, considerado o mais eficiente para a reabilitação das alterações da fala na DP e atualiza os avanços na sua aplicação. Método. Foi realizada uma pesquisa nas bases de dados MEDLINE, Pubmed e Bireme dos artigos indexados publicados de 1990 a 2010, com as seguintes palavras-chave: Parkinson’s disease, PD, Lee Silverman Voice Treatment, LSVT, LSVT LOUD, LSVT parkinson, voice treatment and PD, voice therapy and PD, communication and PD, dysarthria and PD, dysphonia and PD, speech disorders and PD, voice disorders and PD, hypophonia and PD, speech motor system and PD. Resultados. Na literatura, existe ampla descrição dos resultados de estudos do método Lee Silverman na DP. Os artigos encontrados evidenciam melhora da prosódia, articulação, ressonância, respiração, inteligibilidade, intensidade e qualidade da voz, assim como da deglutição e da expressividade facial. Conclusões. Para a reabilitação da fala dispõe-se de eficientes técnicas fonoaudiológicas. Contudo, conforme a literatura científica, o emprego do Método Lee Silverman é opção vantajosa, pois foi desenvolvido especificamente para a DP. Há inúmeras evidências de sua eficácia e vem sendo continuamente avaliado, ampliando sua aplicabilidade.